Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
38.9M
-
Shares change
-
+5.09M
-
Total reported value, excl. options
-
$768M
-
Value change
-
+$104M
-
Put/Call ratio
-
0.84
-
Number of buys
-
82
-
Number of sells
-
-67
-
Price
-
$19.73
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2024
181 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q1 2024.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.9M shares
.
Largest 10 shareholders include BlackRock Inc. (4.19M shares), Fairmount Funds Management LLC (3.2M shares), HHLR ADVISORS, LTD. (3.14M shares), VANGUARD GROUP INC (2.98M shares), BAKER BROS. ADVISORS LP (2.81M shares), Rubric Capital Management LP (2.2M shares), STATE STREET CORP (1.89M shares), PICTET ASSET MANAGEMENT Holding SA (1.46M shares), BRAIDWELL LP (1.39M shares), and MORGAN STANLEY (1.27M shares).
This table shows the top 152 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.